Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK

Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation

(2016) Mark Corbett et al.   HEALTH TECHNOLOGY ASSESSMENT

Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses

(2016) Gillian D. Sanders et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics

(2016) Louise Hamilton et al.   RHEUMATOLOGY

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

(2015) Dominique Baeten et al.   NEW ENGLAND JOURNAL OF MEDICINE

Modeling Health State Utility Values in Ankylosing Spondylitis: Comparisons of Direct and Indirect Methods

(2015) Allan Wailoo et al.   VALUE IN HEALTH

Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study

(2013) Sofia Ramiro et al.   ANNALS OF THE RHEUMATIC DISEASES

The Impact of TNF-inhibitors on radiographic progression in Ankylosing Spondylitis

(2013) Nigil Haroon et al.   ARTHRITIS AND RHEUMATISM

Increased mortality in ankylosing spondylitis is related to disease activity

(2011) G. Bakland et al.   ANNALS OF THE RHEUMATIC DISEASES

Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine

(2008) R Landewe et al.   ANNALS OF THE RHEUMATIC DISEASES

Systematic reviews and economic evaluations conducted for the National Institute for Health and Clinical Excellence in the United Kingdom: A game of two halves?

(2008) Michael F. Drummond et al.   INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE